<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02826213</url>
  </required_header>
  <id_info>
    <org_study_id>PHRI14-JCV-RENOMAP</org_study_id>
    <nct_id>NCT02826213</nct_id>
  </id_info>
  <brief_title>Comparison of Two Techniques of Renal Pre-transplant Infusion on the Evolution of Renal Function in the Recipient</brief_title>
  <acronym>RENOMAP</acronym>
  <official_title>Comparison of Two Techniques of Renal Pre-transplant Infusion on the Evolution of Renal Function in the Recipient: Multicentre Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>INSERM-CIC 1415, University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of two techniques of renal pre-transplant infusion on the evolution of renal
      function in the recipient: multicentre randomized trial
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Both machines differ in their operation: the LifePort® machine manufactured by the &quot;Organ
      Recovery System (ORS),&quot; says renal perfusion by maintaining a continuous perfusion pressure
      that is adjustable, while the Waves machine company &quot;Medical Waters&quot; assures infusion
      maintaining a controlled pulsatile flow.

      Both machines are now available but the investigators currently have no study of whether an
      infusion type is superior to the other in terms of results on renal function recipients.

      Study the impact of both types of infusion on renal function recipients evaluated in the
      early days of transplantation, at three months and one year after the transplant.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 29, 2017</start_date>
  <completion_date type="Anticipated">May 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 28, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Glomerular Filtration Rate</measure>
    <time_frame>3 months</time_frame>
    <description>Rate of patients with a Glomerular Filtration Rate (GFR) calculated by the MDRD ≥ 45 ml / min / 1,73m² (considered normal in a renal graft) at 3 months post-transplantation (MDRD: Modification of Diet in Renal the Disease)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Creatinine &lt;250 mg / dL</measure>
    <time_frame>1 week</time_frame>
    <description>Time for obtaining a serum creatinine &lt;250 mg / dL and need for dialysis in recovery during the first seven days post transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RFG</measure>
    <time_frame>1 month</time_frame>
    <description>Absence of a recovery renal function at 1 month.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MDRD</measure>
    <time_frame>1 year</time_frame>
    <description>Modification of Diet in Renal the Disease at 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GSR</measure>
    <time_frame>1 year</time_frame>
    <description>graft survival rate at 1 year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Biopsie results</measure>
    <time_frame>3 months</time_frame>
    <description>Results of analyzes of kidney biopsies punctures to 3 months.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Transplantation</condition>
  <condition>Kidney</condition>
  <arm_group>
    <arm_group_label>Kidney : perfusion device lifeport</arm_group_label>
    <description>Each donor (n=140) will provide one kidney for pulsatile perfusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kidney : perfusion device waves</arm_group_label>
    <description>Each donor (n=140) will provide one kidney for continuous perfusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LifePort® perfusion device</intervention_name>
    <description>Renal Perfusion with LifePort® perfusion device</description>
    <arm_group_label>Kidney : perfusion device lifeport</arm_group_label>
    <other_name>A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Waves perfusion device</intervention_name>
    <description>Renal Perfusion with Waves perfusion device</description>
    <arm_group_label>Kidney : perfusion device waves</arm_group_label>
    <other_name>B</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        RENAL Donors and recipients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        RENAL Donors:

        Inclusion Criteria:

          -  Deceased donor in brain-dead

          -  Donor presenting the expanded criteria of kidney removal (ECD criteria: elderly over
             60 or aged 50 to 59 years and has two of the three following criteria: hypertension,
             stroke deaths, serum creatinine&gt; 1.5 mg / dL)

          -  Possibility of both kidneys perfused machines

          -  Sampling of both kidneys, for two distinct recipients

        Exclusion Criteria:

        RENAL recipients:

        The grafts are addressed to transplant centers in France according to the distribution
        rules of the National Center of Distribution of transplants . (Pôle National de Répartition
        des Greffons (PNRG).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Christophe VENHARD, MD-PHD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Tours</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Christophe VENHARD, MD-PHD</last_name>
    <phone>+33(0)2 18 37 08 37</phone>
    <email>jc.venhard@chu-tours.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wiebe de JONG, MSc</last_name>
    <phone>+33(0)247474680</phone>
    <email>w.dejong@chu-tours.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Coordination Hospitalière de PMO , Pôle USSAR-Anestéthésie -Réa CHU-ANGERS</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent DUBÉ, MD-PHD</last_name>
      <phone>+33241355238</phone>
      <email>ladube@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Laurent DUBÉ, MD-PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coordination Hospitalière de PMO-Anestésiste -réanimateur, CHU-Bordeaux -GROUPE HOSPITALIER PELLEGRIN DAR I</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent STECKEN, MD-PHD</last_name>
      <phone>+33556796160</phone>
      <email>laurent.stecken@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Julien ROGIER, MD-PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent STECKEN, MD-PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHD-Vendée-Les Oudairies</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent Martin-Lefèvre, MD-PHD</last_name>
      <phone>+33251446212</phone>
      <email>laurent.martin-lefevre@chd-vendee.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Coordination des prélèvements d'organes et de Tissus- CHU-Limoges -CHU- DUPUYTREN</name>
      <address>
        <city>Limoges</city>
        <zip>84042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas PICHON, MD-PHD</last_name>
      <phone>+33555056240</phone>
      <email>nicolas.pichon@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas PICHON, MD-PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chirurgien-Chirurgie de la transplantation et d'Urologie, Pavillon V, Hôpital Edouard HERRIOT</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lionel BADET, MD-PHD</last_name>
      <phone>+33472110538</phone>
      <email>lionel.badet@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Lionel BADET, MD-PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coordination des prélèvements d'organes et de Tissus,CHU-NANTES</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Martin-Lefèvre, MD-PHD</last_name>
      <phone>+33253482223</phone>
      <email>laurent.martin-lefevre@chd-vendee.fr</email>
    </contact>
    <investigator>
      <last_name>Michel VIDECOQ, MD-PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent Martin-Lefèvre, MD-PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de réanimation chirurgicale et Unité de prélèvement d'organes et de tissus,CHU-POITIERS- LA MILETRIE</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas KERFORNE, MD-PHD</last_name>
      <phone>+33549443026</phone>
      <email>thomas.kerforne@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>Thomas KERFORNE, MD-PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thierry BENARD, MD-PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coordination des prélèvements d'organes et de Tissus Pôle Anesthésie-Réanimations,University Hospital</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Christophe VENHARD, MD-PHD</last_name>
      <phone>+33218370837</phone>
      <email>jc.venhard@chu-tours.fr</email>
    </contact>
    <contact_backup>
      <last_name>Wiebe de JONG, MSc</last_name>
      <phone>+33247474680</phone>
      <email>w.dejong@chu-tours.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-Christophe VENHARD, MD-PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2016</study_first_submitted>
  <study_first_submitted_qc>July 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2016</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal infusion</keyword>
  <keyword>Renal infusion device</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

